Correction: Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC

Affiliations

• ¹ Department of Biomedical Sciences, Humanitas University, Milan, Italy. armando.santoro@cancercenter.humanitas.it.
• ² Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Via Manzoni 56, Rozzano, Milan, 20089, Italy. armando.santoro@cancercenter.humanitas.it.
• ³ Department of Medical Oncology, Hospital Ramón Y Cajal, Madrid, Spain.
• ⁴ Department of Medical Oncology, National Cancer Center Singapore, Singapore, Singapore.
• ⁵ Department of Medical Oncology, University Hospital, 12 de Octubre, Madrid, Spain.
• ⁶ Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
• ⁷ Department of Medical Oncology, Centro Di Riferimento Oncologico - CRO, Aviano, Italy.
• ⁸ Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, CNRS, INSERM, CRCM, APHM, CEPCM, CLIP, Marseille, France.
• ⁹ Faculté de Médecine, Université Paris Saclay, Kremlin Bicêtre, France.
• ¹⁰ Medical Oncology Department, Gustave Roussy, Villejuif, France.
• ¹¹ Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
• ¹² Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
• ¹³ Department of Medical Oncology Service, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
• ¹⁴ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
• ¹⁵ Novartis Pharma AG, Basel, Switzerland.
• ¹⁶ Department of Medical Oncology, Highlands Oncology Group, Fayetteville, AZ, USA.